🔗 Permalink

Inventor profile of:

Claudio Pietra

City:

Como

Country:

Italy

Published Applications:

Last publication date:

2023-05-25

Top Assignees for applications by Claudio Pietra

The entities that hold a legal rights for patent applications filed by inventor Pietra Claudio:

Helsinn Healthcare SA 13 Lugano/Pazzallo, Switzerland
Helsinn Healthcare SA 4 Pazzallo Lugano, Switzerland
Helsinn Healthcare SA 2 Lugano/ Pazzallo, Switzerland
Helsinn Healthcare SA 1 Lugano/Passallo, Switzerland
Helsinn Healthcare S.A. 1 Pambio-Noranco, Switzerland
Helsinn Healthcare SA 1 Pazzallo/Lugano, -

Recent patent applications by Pietra Claudio

Claudio Pietra from Como, IT has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2023-05-25

US20230158007A1

Human necessities

Centrally-active ghrelin agonist and medical uses thereof

#2 | 2022-12-22

US20220401463A1

Human necessities

Process for the synthesis of substituted chloromethyl dialkylphosphates

#3 | 2022-10-27

US20220340541A1

Chemistry; metallurgy

Fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea, methods of preparation, and uses thereof

#4 | 2020-12-24

US20200399240A1

Chemistry; metallurgy

Fosnetupitant chloride hydrochloride having improved stability

#5 | 2020-09-24

US20200299260A1

Chemistry; metallurgy

Fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2- trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, methods of preparation, and uses thereof

#6 | 2020-08-20

US20200262850A1

Chemistry; metallurgy

SUBSTITUTED ASYMMETRIC UREAS AS MODULATORS OF GHRELIN RECEPTOR ACTIVITY

#7 | 2019-06-13

US20190177296A1

Chemistry; metallurgy

Substituted piperaziniums for the treatment of emesis

#8 | 2019-02-28

US20190062352A1

Chemistry; metallurgy

Substituted asymmetric ureas as modulators of ghrelin receptor activity

#9 | 2018-07-12

US20180194788A1

Chemistry; metallurgy

Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator

#10 | 2018-06-28

US20180177849A1

Human necessities

Therapeutic Uses of Elsiglutide

#11 | 2018-02-15

US20180044293A1

Chemistry; metallurgy

Asymmetric ureas and medical uses thereof

#12 | 2017-09-28

US20170275301A1

Chemistry; metallurgy

Benzenesulfonyl-asymmetric ureas and medical uses thereof

#13 | 2017-05-25

US20170145038A1

Chemistry; metallurgy

Substituted asymmetric ureas as modulators of ghrelin receptor activity

#14 | 2017-03-30

US20170087216A1

Human necessities

Therapeutic Uses of Elsiglutide

#15 | 2017-02-23

US20170050993A1

Chemistry; metallurgy

Substituted piperaziniums for the treatment of emesis

#16 | 2015-09-10

US20150252021A1

Chemistry; metallurgy

Asymmetric piperidinyl-substituted ureas as medicines

#17 | 2015-01-08

US20150011510A1

Chemistry; metallurgy

4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator

#18 | 2014-09-11